The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results

Category Primary study
JournalJournal of Clinical Oncology
Year 2019
This article has no abstract
Epistemonikos ID: bd32d32365b0c4cdfeef7f8c7ea7fa626f7cc56e
First added on: Feb 11, 2025